| Full text | |
| Author(s): |
Andre, Nayara Delgado
[1]
;
Oliveira Silva, Viviane Aline
[2]
;
Ehara Watanabe, Maria Angelica
[3]
;
De Lucca, Fernando Luiz
[4]
Total Authors: 4
|
| Affiliation: | [1] Univ Fed Sao Joao Del Rei, BR-35501296 Divinopolis, MG - Brazil
[2] Barretos Canc Hosp, Mol Oncol Res Ctr, BR-14784400 Barretos, SP - Brazil
[3] Univ Estadual Londrina, Dept Pathol Sci, Ctr Biol Sci, BR-86057970 Londrina, PR - Brazil
[4] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Biochem & Immunol, BR-14049900 Ribeirao Preto, SP - Brazil
Total Affiliations: 4
|
| Document type: | Journal article |
| Source: | ONCOLOGY REPORTS; v. 35, n. 4, p. 2419-2424, APR 2016. |
| Web of Science Citations: | 2 |
| Abstract | |
The incidence of malignant melanoma has increased greatly in recent decades presenting a high mortality rate despite intensive efforts in this area of research. Recent studies indicate that the chemokine receptor 4 (CXCR4) plays a critical role in cancer. Thus, it has been reported that CXCL12 binding to CXCR4 initiates various downstream signaling pathways that result in a plethora of responses involved in cell proliferation and metastasis. Recently, we demonstrated that CXCR4 silencing by RNA interference (RNAi) significantly reduced the number of pulmonary metastatic nodules. In the present study, we examined the effect of the intratumoral injection of CXCR4 short hairpin (shRNA) expressing plasmids on the growth of B16-F10 melanoma in mice. In vitro transfection of these tumor cells with CXCR4 shRNA expressing plasmid (CXCR4 shRNA) significantly reduced the levels of CXCR4 mRNA (85%) and CXCR4 protein (70%) compared with the control. We showed that the tumor growth was significantly reduced (66%) in mice inoculated with transfected B16-F10 melanoma cells when compared with the control group. We also found that the intratumoral injection of CXCR4 shRNA expressing plasmids results in a significant inhibition (70%) of B16-F10 melanoma growth. This finding supports the hypothesis that a direct administration of RNAi-based therapeutics into the target tumor is a promising approach for overcoming the hurdles of systemic delivery. The present study is the first demonstration that CXCR4 plays a critical role in B16-F10 melanoma growth. Currently there is great interest in the development of antagonists for therapeutic targeting CXCR4 expression. Considering our results and the fact that CXCR4 is highly conserved between human and mouse, this experimental model of cancer may be useful for the discovery of new CXCR4 antagonists with clinical implications. (AU) | |